Adhera Therapeutics (ATRX) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 16, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-13789
Entity Registrant Name	ADHERA THERAPEUTICS, INC.
Entity Central Index Key	0000737207
Entity Tax Identification Number	11-2658569
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8000 Innovation Parkway
Entity Address, City or Town	Baton Rouge
Entity Address, State or Province	LA
Entity Address, Postal Zip Code	70820
City Area Code	(919)
Local Phone Number	518-3748
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,493,237

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash	$ 40	$ 76
Prepaid expenses	130	120
Total current assets	170	196
Total assets	170	196
Current liabilities
Accounts payable	2,287	2,309
Due to related parties	76	46
Accrued expenses	3,467	3,110
Accrued dividends	5,841	5,477
Term loan	5,677	5,677
Convertible notes payable, net	1,151	986
Derivative liability	7,169	7,697
Total current liabilities	25,668	25,302
Total liabilities	25,668	25,302
Commitments and contingencies (Note 9)
Stockholders’ deficit
Preferred stock
Common stock, $0.006 par value; 180,000,000 shares authorized, 17,493,237 and 16,998,836 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	105	102
Additional paid-in capital	27,852	27,809
Accumulated deficit	(53,455)	(53,017)
Total stockholders’ deficit	(25,498)	(25,106)
Total liabilities and stockholders’ deficit	170	196
Series C Convertible Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series D Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series E Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series F Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series G Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Common stock, par value	$ 0.006	$ 0.006
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	17,493,237	16,998,836
Common stock, shares outstanding	17,493,237	16,998,836
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,200	1,200
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100
Preferred stock, liquidation preference value	$ 510,000	$ 510,000
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	220	220
Preferred stock, shares issued	40	40
Preferred stock, shares outstanding	40	40
Preferred stock, liquidation preference value	$ 12,000	$ 12,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	3,500	3,500
Preferred stock, shares issued	3,326	3,326
Preferred stock, shares outstanding	3,326	3,326
Preferred stock, liquidation preference value	$ 21,948,470	$ 21,948,470
Series F Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,200	2,200
Preferred stock, shares issued	358	358
Preferred stock, shares outstanding	358	358
Preferred stock, liquidation preference value	$ 2,313,603	$ 2,313,603
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,000	6,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 5,000	$ 5,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses
Sales and marketing		$ 9
General and administrative	260	101
Total operating expenses	260	110
Loss from operations	(260)	(110)
Other income (expense)
Interest expense	(311)	(243)
Initial and change in fair value of derivative liability	667
Gain on extinguishment of debt	5
Amortization of debt discount	(175)	(75)
Total other income (expense)	186	(318)
Net loss	(74)	(428)
Accrued and deemed dividends	(364)	(882)
Net Loss Applicable to Common Stockholders	$ (438)	$ (1,310)
Net loss per share - Common Stockholders, basic and diluted	$ (0.03)	$ (0.12)
Weighted average shares outstanding, basic and diluted	17,179,188	11,187,531

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Preferred Stock [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Series D Preferred Stock [Member]	Preferred Stock [Member]Series E Preferred Stock [Member]	Preferred Stock [Member]Series F Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020					$ 67	$ 29,772	$ (44,612)	$ (14,773)
Beginning balance, shares at Dec. 31, 2020	100	40	3,458	361	11,112,709
Accrued and deemed dividend						505	(882)	(377)
Issuance of common stock for convertible note conversions					$ 3	23		26
Issuance of common stock for convertible note conversions, shares					518,000
Issuance of warrants with convertible notes						28		28
Beneficial conversion feature convertible notes						19		19
Net loss							(428)	(428)
Ending balance, value at Mar. 31, 2021					$ 70	30,347	(45,922)	(15,505)
Balance, shares at Mar. 31, 2021	100	40	3,458	361	11,630,709
Beginning balance, value at Dec. 31, 2021					$ 102	27,809	(53,017)	(25,106)
Beginning balance, shares at Dec. 31, 2021	100	40	3,326	358	16,988,836
Issuance of common stock for convertible note conversions					$ 2	26		$ 28
Issuance of common stock for convertible note conversions, shares					254,401			2,665,663
Net loss							(74)	$ (74)
Accrued dividend							(364)	(364)
Issuance of common stock with convertible notes					$ 1	17		18
Issuance of common stock with convertible notes, shares					250,000
Ending balance, value at Mar. 31, 2022					$ 105	$ 27,852	$ (53,455)	$ (25,498)
Balance, shares at Mar. 31, 2022	100	40	3,326	358	17,493,237

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash Flows Used in Operating Activities:
Net loss	$ (74,000)	$ (428,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and fees	175,000	77,000
Accrued interest expense	311,000	241,000
Derivative expense	(667,000)
Gain on debt extinguishment	(5,000)
Changes in operating assets and liabilities:
Prepaid expenses	(10,000)
Accounts payable	8,000	(2,000)
Accrued expenses	46,000	66,000
Net Cash Used in Operating Activities	(216,000)	(46,000)
Cash Flows Provided by Financing Activities:
Proceeds from notes payable, net of original issue discounts	200,000	48,000
Notes payable issuance costs	(20,000)	(2,000)
Net Cash Provided by Financing Activities	180,000	46,000
Net increase (decrease) in cash	(36,000)
Cash – Beginning of Year	76,000	1,000	$ 1,000
Cash - End of Year	40,000	1,000	$ 76,000
Non-cash Investing and Financing Activities:
Cash paid for interest
Cash paid for taxes
Debt discounts for issuance costs, warrants and derivatives	18,000	28,000
Beneficial conversion feature		19,000
Issuance of common stock for conversion of convertible notes	28,000	26,000
Accrued and deemed dividends	$ 364,000	$ 882,000

Organization and Business Opera

Organization and Business Operations	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	Note 1 – Organization and Business Operations Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company. On July 28, 2021, we as licensee and Melior Pharmaceuticals II, LLC entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of our knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, we were granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales. On August 20, 2021, we as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. On October 20, 2021, we as licensee expanded the exclusive licensing agreement with Melior Pharmaceuticals I, Inc. to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. To the extent that resources have been available, the Company has continued to work with its advisors in an effort to restructure our company and to identify potential strategic transactions to enhance the value of our company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to our legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the Company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to us or at all. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the near future, it is likely that the Company will discontinue all operations and seek bankruptcy protection.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results for the year ending December 31, 2022 or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2022, the Company had cash and cash equivalents of approximately $ 40,000 25.5 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $ 74,000 216,000 53.5 In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issues arising from the COVID-19 pandemic, the Ukraine war and inflation and the Federal Reserve interest rate increases in response, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of March 31, 2022, the Company had approximately $ 40,000 The Company deposits its cash with major financial institutions and may at times exceed the federally insured limit. At March 31, 2022, the Company’s cash balance did not exceed the federal insurance limit. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of March 31, 2022, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.2 1.63 2.45 244.5 309.03 0.88 no Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at March 31, 2022 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,169 $ 7,169 Total $ - $ - $ 7,169 $ 7,169 A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (In thousands) Warrants Notes Total Three-Months Ended March 31, 2022 (In thousands) Warrants Notes Total Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 Initial valuation of derivative liabilities included in debt discount — 163 163 Initial valuation of derivative liabilities included in derivative expense — 10 8 108 Reclassification of derivative liabilities loss to gain on debt extinguishment — (23 ) (23 ) Change in fair value included in derivative expense (103 ) (673 ) (776 ) Balance at March 31, 2022 $ 5,233 $ 1,936 $ 7,169 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt. Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year. The adoption by the Company as of January 1, 2022 did not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2022 2021 March 31, (in thousands except share and per share data) 2022 2021 Numerator Net loss $ (74 ) $ (428 ) Preferred stock dividends (364 ) (882 ) Net Loss allocable to common stockholders $ (438 ) $ (1,310 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 17,179,188 11,187,531 Net loss per share of common stock, basic and diluted Net loss per share, basic and diluted $ (0.03 ) $ (0.12 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Three-Months Ended March 31, 2022 2021 Stock options outstanding 380,000 387,550 Convertible notes 53,901,211 18,785,631 Warrants 79,316,071 62,532,312 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 43,896,887 42,737,413 Series F Preferred Stock 4,627,203 4,374,978 Total 182,238,039 128,934,551 As of March 31, 2022, the Company’s fully diluted common stock equivalents exceeded the 180,000,000 Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.

Prepaid Expenses

Prepaid Expenses	3 Months Ended
	Mar. 31, 2022
Prepaid Expenses
Prepaid Expenses	Note 3 – Prepaid Expenses As of March 31, 2022, and December 31, 2021 prepaid expenses totaled approximately $ 130,000 and $ 120,000 , respectively and included prepaid manufacturing expenses for the Company’s clinical development candidate MLR recorded on the accompanying balance sheet.

Notes Payable and Convertible P

Notes Payable and Convertible Promissory Notes	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Notes Payable and Convertible Promissory Notes	Note 4 – Notes Payable and Convertible Promissory Notes 2019 Term Loans During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes in the aggregate principal amount of approximately $ 5.7 million (collectively, the “2019 Term Loans”). The Company paid $ 707,000 in debt issuance costs which was recorded as a debt discount to be amortized as interest expense over the term of the loan using the straight-line method. The promissory notes accrued interest at a rate of 12% 15% The unpaid principal balance of the notes, plus accrued and unpaid interest thereon, matured on June 28, 2020 . The notes were secured by a first lien and security interest on all the assets of the Company and certain of its wholly owned subsidiaries. On June 28, 2020, the Company defaulted on the maturity date principal payment. In June 26, 2021, the holders of the 2019 Term Loans agreed to subordinate their lien and security interest in the assets of the Company and its subsidiaries as set forth in the Security Agreement dated June 28, 2019 to the holders of the June 2021 convertible notes. The Company recognized approximately $ 210,000 in interest expense related to the Notes for the three months ended March 31, 2022 and March 31, 2021. As of March 31, 2022, the debt discount and issuance costs for this term loan were fully amortized. As of March 31, 2022, the Company had approximately $ 2.2 million of accrued interest on the notes included in accrued expenses and remains in default on the repayment of approximately $ 5.7 million in principal and $ 2.2 million in accrued interest on the 2019 Term Loans. Convertible Promissory Notes The following table summarizes the Company’s outstanding convertible notes as of March 31, 2022, and December 31, 2021: Schedule of Convertible Promissory Notes (in thousands) March 31, 2022 December 31, 2021 Convertible Notes $ 1,756 $ 1,516 Unamortized discounts and fees (605 ) (530 ) Convertible Notes Payable $ 1,151 $ 986 Ten convertible notes with outstanding principal of approximately $ 1.5 Secured Convertible Promissory Note – February 2020 On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes with a principal of $ 550,500 issued at a 10% original issue discount, for a total purchase price of $ 499,950 , and (ii) warrants to purchase up to such number of shares of the common stock of the Company as is equal to the product obtained by multiplying 1.75 by the quotient obtained by dividing (A) the principal amount of the Notes by (B) the then applicable conversion price of the Notes. This results in a variable quantity of warrants at any point in time due to the variable conversion price of the Notes. (See Note 7) The Convertible Notes matured on August 5, 2020 10% 18% Until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $ 0.50 70% 60% 0.05 The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5 The Company recorded a discount related to the Warrants of approximately $ 322,000 30,000 53,000 21,000 38,000 381,000 On March 19, 2021, the holder of the Convertible Note converted $ 25,900 518,000 On July 29, 2021, the holder of the Convertible Note converted $ 27,500 550,000 On August 16, 2021, the holder of the Convertible Note converted $ 25,000 500,000 On September 13, 2021, the holder of the Convertible Note converted $ 32,500 650,000 On October 4, 2021, the holder of the Convertible Note converted $ 26,250 525,000 On November 29, 2021, the holder of the Convertible Note converted $ 31,150 623,012 The total note principal and interest converted during the year ended December 31, 2021, was $ 168,300 3,366,012 554,000 386,000 245,000 245,000 141,000 On January 27, 2022, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60% 0.039 For the three months ended March 31, 2022, and March 31, 2021, the Company recognized approximately $ 25,000 in interest expense related to the note As of March 31, 2022, the Company had accrued interest on the February 2020 Convertible Note of approximately $ 126,000 As of March 31, 2022, the Company remains in default on the repayment of remaining principal of $ 457,359 and accrued interest on the February 2020 Convertible Notes. Upon demand for repayment at the election of the holder, the holder of the Convertible Note is due 140% of the aggregate of outstanding principal, interest, and other expenses due in respect of this Convertible Note. The 40% premium will be recorded once a demand occurs . Secured Convertible Promissory Note – June 2020 On June 26, 2020, the Company issued to an existing investor in the Company a 10% 58,055 52,500 5,555 December 26, 2020 10% 14,000 18% The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.02 65% 50,000 203,000 The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $ 5.7 On January 27, 2022, the conversion price of the note was adjusted to the lower of 65% of the lowest closing bid price of the Company’s common stock as reported on its principal trading market for the twenty consecutive trading day period ending on (and including) the trading day immediately preceding the date on which the conversion notice was delivered or $ 0.039 as a result of issuance of common shares for a convertible note conversion. For the three-month period ended March 31, 2022, and March 31, 2021, the Company recognized approximately $ 2,600 As of March 31, 2022, the Company remains in default on the repayment of principal of $ 58,055 18,000 140% The 40% premium will be recorded once a demand occurs Secured Convertible Promissory Note – October 2020 On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10% original issue discount senior secured convertible promissory note with a principal of $ 111,111 , for a purchase price of $ 100,000 . The note is convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.07 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of then conversion price. The conversion price of the notes is subject to anti-dilution price protection and on March 19, 2021, the conversion price of the notes was adjusted to $ 0.05 per share as a result of subsequent equity sales by the Company. The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company. The Company recorded approximately $ 9,000 The interest rate on the note was 10% 18% Additionally, the Company issued the noteholder 1,587,301 0.08 0.05 952,379 57,000 0.16% 262.27% 0.92 The Company recorded a discount related to the warrants of approximately $ 66,000 6,000 5,000 45,000 69,000 5,000 4,000 On January 27, 2022, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.049 0.039 as a result of a convertible note exercise and the Company issued an additional 716,320 warrants to the note holder. For the three months ended March 31, 2022, the Company recognized approximately $ 5,000 4,700 1,900 57,000 As of March 31, 2022, the debt discount and issuance costs for the note were fully amortized. As of March 31, 2022, the Company has outstanding principal of $ 111,111 24,000 As of March 31, 2022, the Company remains in default on the repayment of principal and interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – January 202 On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10% original issue discounted Senior Secured Convertible Promissory Note with a principal of $ 52,778 , for a purchase price of $ 47,500 , net of original issue discount of $ 5,278 . The Note was convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.07 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of the then conversion price. The conversion price of the notes is subject to anti-dilution price protection and will be adjusted upon subsequent equity sales by the Company. The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. Additionally, the Company issued to the investor 753,968 0.08 0.05 452,372 27,000 0.16% 262.27% 0.97 The Company recorded approximately $ 2,000 The interest rate on the note was 10% 18% The Company recorded a discount related to the warrants of approximately $ 32,000 3,000 1,000 0.45% 240.83% The Company also recorded a debt discount related to the convertible debt of approximately $ 2,000 1,000 Total discounts recorded including the original issue discount were approximately $ 35,000 On January 27, 2022, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.049 0.039 as a result of a convertible note exercise and the Company issued an additional 340,250 warrants to the note holder. For the year ended March 31, 2021, the Company recognized approximately $ 1,200 300 18,000 For three months ended March 31, 2022, the Company recognized approximately $ 2,400 As of March 31, 2022, the Company has outstanding principal of $ 52,778 9,000 As of March 31, 2022, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – April 2021 On April 12, 2021, the Company issued to an accredited investor in and lender to the Company a 10% 66,667 60,000 6,667 800,000 five 0.095 The note matured on October 12, 2021, Prior to default, interest accrued on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10% 18% The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 0.075 70% The Company recorded a discount related to the warrants of approximately $ 34,000 3,700 3,000 0.89% 240.64% one year On June 25, 2021, the exercise price of the warrants was adjusted to $ 0.075 213,333 11,000 0.92% 247.52% 0.96 On November 4, 2021, the Company issued 153,227 250,000 On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 0.05 131,667 On January 27, 2022, the exercise price of the note and warrants was adjusted from the default conversion price of $ 0.0525 0.039 based on a convertible note conversion at $ 0.039 and the Company issued an additional 322,949 warrants to the note holder. For the three months ended March 31, 2022, the Company recognized approximately $ 3,000 As of March 31, 2022, the Company has recorded $ 66,667 9,100 As of March 31, 2022, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – June 2021 On June 25, 2021, the Company issued to an accredited investor in and lender to the Company a 5% original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $ 66,500 , for a purchase price of $ 63,000 , net of an original issue discount of $ 3,500 . Additionally, the Company issued to the investor 800,000 three -year warrants to purchase the Company’s common stock at an exercise price of $ 0.095 per share. Upon subsequent down-round equity sales by the Company, the number of shares issuable upon exercise of the Warrant shall be proportionately adjusted such that the aggregate exercise price of this Warrant shall remain $ 76,000 which is a full ratchet price protection provision. The note matures on June 25, 2022 10% The Note was convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 0.075 (as adjusted for stock splits, stock combinations and similar events); provided, however that in the event, the Company’s Common Stock trades below $ 0.08 per share for more than three (3) consecutive trading days, the holder of this Note is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to 65% of the lowest trading price of the Common Stock for the twenty prior trading days including the day upon which a Notice of Conversion is received. The conversion discount, look back period and other terms of the Note will be adjusted on a ratchet basis if the Company offers a more favorable conversion discount, prepayment rate, interest rate, (whether through a straight discount or in combination with an original issue discount), look back period or other more favorable term to another party for any financings while this Note is in effect The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. The Company incurred approximately $ 9,300 The Company also issued 47,547 5,040 Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 102,823 87,039 15,784 Total discounts recorded were $ 66,500 3,500 9,300 37,916 15,784 0.48 302.11% 0.60 On August 11, 2021, the exercise price of the warrants was adjusted to $ 0.075 213,333 25,000 0.81 209% 0.57 On October 27, 2021, the Company and the institutional investor who holds the convertible promissory note agreed to extend the maturity date of the note by six months to December 25, 2022 for no consideration. On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 0.05 506,667 On January 27, 2022, the holder of the June 25, 2021, convertible note converted $ 9,500 of principal and $ 421 of interest at $ 0.039 per share into 254,401 shares of common stock that were valued at fair value based on the quoted trading prices on the conversion dates aggregating approximately $ 28,000 resulting in a loss on debt extinguishment of $ 18,000 . In addition, derivative fair value of $ 23,000 relating to the portion of the Note converted was settled resulting in a gain on extinguishment of approximately $ 23,000 . The net gain on extinguishment was approximately $ 5,000 . 0.039 428,718 For the three months ended March 31, 2022, the Company recognized approximately $ 9,800 3,500 At March 31, 2022, the Company has recorded $ 57,000 8,800 28,900 Convertible Promissory Note – August 11, 2021 On August 11, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 800,000 210,000 10,500 100,000 The note matures one year from issuance and absent an event of default provides for an interest rate of 10% 0.075 65% 24% In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The warrants are initially exercisable for a period of three years at a price of $ 0.095 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the warrant. The Company incurred approximately $ 30,000 The Company also issued 140,000 Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 340,893 234,388 106,505 The Company recorded a total debt discount of $ 220,500 10,500 56,454 30,000 17,041 106,505 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.81% 253% one year On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 0.05 720,000 On January 27, 2022, the conversion price of the notes was adjusted to the lower of $ 0.039 65% 0.039 428,718 0.039 For the three months ended March 31, 2022, the Company recognized approximately $ 54,400 12,400 At March 31, 2022, the Company has remaining $ 220,500 28,200 79,700 Convertible Promissory Note – August 17, 2021 On August 17, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 and warrants to purchase 800,000 shares of the common stock of the Company for which the Company received consideration of $ 210,000 net of original discount of $ 10,500 . In addition, the Company entered into a Registration Rights Agreement with the investor and issued the investor 100,000 common shares as a commitment fee. The note matures one year 10% 0.075 0.08 65% In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The Warrants are initially exercisable for a period of three years at a price of $ 0.095 The Company incurred approximately $ 30,000 112,601 Due to the variability in the conversion price of the Note, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 398,404 297,833 100,571 The Company recorded a total debt discount of $ 220,500 10,500 62,220 30,000 17,209 100,571 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.77% 254% one year On October 27, 2021, the Company and the institutional investor who holds the promissory note agreed to extend the maturity date the notes by six months to February 17, 2023 On November 15, 2021, the Company defaulted on certain covenants in the note and the interest rate on the note reset to 24% On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 0.05 720,000 On January 27, 2022, the conversion price of the notes was adjusted to the lower of $ 0.039 65% 0.039 428,718 0.039 For the three months ended March 31, 2022, the Company recognized approximately $ 34,700 12,400 At March 31, 2022, the Company has recorded $ 220,500 27,800 123,200 Convertible Promissory Note – October 4, 2021 On October 4, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10% Convertible Redeemable Note in the principal amount of $ 131,250 and a three-year warrant to purchase 476,190 shares of common stock of the Company for which the Company received proceeds of $ 110,000 . In addition, the Company entered into a Registration Rights Agreement with the investor and issued the investor 59,523 common shares as a commitment fee. The Note is due October 4, 2022. The Note provides for interest at the rate of 10% 0.075 The Warrants are exercisable for three-years from October 4, 2021, at an exercise price of $ 0.095 45,238 The Company incurred approximately $ 15,000 43,459 Due to the lack of authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,943 487,052 77,891 The Company recorded a total debt discount of $ 131,250 6,250 15,000 32,109 77,891 On January 2, 2022, the Company defaulted on certain covenants contained in the October 4, 2021, convertible note and the interest rate reset to 16% . On January 27, 2022, the exercise price of the note was adjusted to $ 0.039 0.039 For the three months ended March 31, 2022, the Company recognized approximately $ 32,400 5,000 At March 31, 2022, the Company has recorded $ 131,250 8,200 66,900 Convertible Promissory Note – October 7, 2021 On October 7, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the investor a 10% Convertible Redeemable Note in the principal amount of $ 131,250 and a three-year warrant to purchase 476,190 shares of common stock of the Company for which the Company received proceeds of $ 110,000 . In addition, the Company entered into a Registration Rights Agreement with the investor and issued the investor 59,523 common shares as a commitment fee and an additional 52,632 shares as a commission to the broker. The Note is due October 7, 2022. The Note provides for interest at the rate of 10% per annum, payable at maturity. The Note was convertible into shares of common stock at any time following the date of cash payment at the investor’s option at a conversion price of $ 0.075 per share, subject to certain adjustments. The Warrants are exercisable for three-years from October 7, 2021, at an exercise price of $ 0.095 45,238 The Company incurred approximately $ 15,000 Due to the lack of authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,184 487,667 76,517 The Company recorded a total debt discount of $ 131,250 6,250 15,000 33,483 76,517 On January 5, 2022, the Company defaulted on certain covenants contained in the October 7, 2021, convertible note and the interest rate reset to 16% . On January 27, 2022, the exercise price of the note was adjusted to $ 0.039 0.039 For the three months ended March 31, 2022, the Company recognized approximately $ 32,400 5,000 At March 31, 2022, the Company has recorded $ 131,250 8,100 68,000 Convertible Promissory Note – March 15, 2022 On March 15, 2022, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the investor a 10% Convertible Note in the principal amount of $ 250,000 for a purchase price of $ 200,000 reflecting a $ 50,000 original issue discount. The Company received total consideration of $ 180,000 after debt issuance costs of $ 20,000 . In addition, the Company issued 50,000 shares of common stock as a commitment fee to the investor. The Company also issued 200,000 shares to the broker as a commission on the sale. The Note provides for guaranteed interest at the rate of 10% 25,000 39,285.71 The Note is convertible into shares of common stock at any time following any event of default at the investor’s option at a conversion price of ninety percent (90%) per share of the lowest per-share trading price of the Company; stock during the ten trading day periods before the conversion, subject to certain adjustments. The Company recorded a total debt discount of $ 250,000 including an original issue discount of $ 50,000 , a discount related to issuance costs of $ 34,384 a discount related to the issuance of common stock of approximately $ 3,596 and a $162,020 discount related to the initial derivative value of the embedded conversion feature on the Note all based on the relative fair value of the instruments. The discounts are being amortized over the life of the convertible note. For the three months ended March 31, 2022, the Company recognized approximately $ 11,600 25,000 At March 31, 2022, the Company has recorded $ 250,000 25,000 238,400 Derivative Liabilities Pursuant to Convertible Notes and Warrants In connection with the issuance of the unrelated party convertible notes (collectively referred to as “Notes”) and warrants (collectively referred to as “Warrants”), discussed above, the Company determined that the terms of certain Notes and Warrants contain an embedded conversion options to be accounted for as derivative liabilities due to the holder having the potential to gain value upon conversion and provisions which includes events not within the control of the Company. Due to the fact that the number of shares of common stock issuable exceed the Company’s authorized share limit as of March 31, 2022, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative. In accordance with ASC 815-40 – Derivatives and Hedging – Contracts in an Entity’s Own Stock During the three month period ended March 31, 2022, in connection with the issuance of the Notes, on the initial measurement dates, the fair values of the embedded conversion option of approximately $ 271,000 was recorded as derivative liabilities of which $ 163,000 was allocated as a debt discount and $ 108,000 as derivative expense. At the end of the period, the Company revalued the embedded conversion option derivative liabilities. In connection with the initial valuations and these revaluations, the Company recorded a gain from the initial and change in the derivative liabilities fair value of approximately $ 776,000 During the three months period ended March 31, 2022, the fair value of the derivative liabilities was estimated at issuance and at March 31, 2022, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.0 0.88 Volatility 245 309 % Risk-free interest rate 1.28 2.45 % Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain convertible notes to reduce the conversion price to $ 0.039

Licensing Agreements

Licensing Agreements	3 Months Ended
	Mar. 31, 2022
Licensing Agreements
Licensing Agreements	Note 5 - Licensing Agreements License of DiLA 2 On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $ 200,000

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 - Related Party Transactions Due to Related Party The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous. The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018. An unpaid balance for previous years services performed under the agreement of approximately $ 4,000 In addition, as of March 31, 2022, and December 31, 2021, the Company owed various officers and directors approximately $ 72,000 42,000

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Equity	Note 7 - Stockholders’ Equity Preferred Stock Adhera has authorized 100,000 shares of preferred stock for issuance and has designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series A Preferred or Series B Preferred are outstanding. In March 2014, Adhera designated 1,200 shares as Series C Convertible Preferred Stock (“Series C Preferred”). In August 2015, Adhera designated 220 shares as Series D Convertible Preferred Stock (“Series D Preferred”). In April 2018, Adhera designated 3,500 shares of Series E Convertible Preferred Stock (“Series E Preferred”). In July 2018, Adhera designated 2,200 shares of Series F Convertible Preferred Stock (“Series F Preferred”). In December 2019, Adhera designated 6,000 shares of Series G Convertible Preferred Stock (“Series G Preferred”). The Company plans to file a certificate of elimination with respect to the Series A Preferred and Series B Preferred and a certificate of decrease with respect to each of its Series C, D and F Preferred stock. As of March 31, 2022, the Company had not filed the certificate of elimination. Each subsequent designated series of preferred stock has liquidation preference over the previous series. Series C Preferred Each share of Series C Preferred has a stated value of $ 5,000 5,100 voting rights of 666.67 votes per share 7.50 As of March 31, 2022, and December 31, 2021, 100 Series D Preferred Each share of Series D Preferred has a stated value of $ 5,000 300 voting rights of 1,250 4.00 5 As of March 31, 2022, and December 31, 2021, 40 Series E Convertible Preferred Stock and Warrants The Series E Preferred Stock has a stated value of $ 5,000 8 0.50 February 10, 2020 On March 19, 2021, the exercise price of the Series E warrants was adjusted from $ 0.50 0.05 25,900 518,000 390,000 0.16 262.27 .41 .43 As of May 17, 2021, the three-year anniversary of the closing of the Series E Preferred stock offering, all outstanding Series E Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders. As of March 31, 2022, the Company has not provided notice of conversion to the holders of the Series E Preferred stock. On June 8, 2021, an investor converted 8 10,000 101,010 53,571 75,000 On July 30, 2021, an investor converted 50 250,000 500,000 On October 4, 2021, the Company issued 255,540 20 27,770 On October 5, 2021, the Company issued 385,414 30 42,707 On October 8, 2021, the Company issued 51,414 4 5,707 On October 12, 2021, the Company issued 64,312 5 7,156 On November 23, 2021, the Company issued 193,299 15 21,649 On January 27, 2022, the exercise price of the Series E warrants was adjusted to $ 0.039 0.039 As of March 31, 2022, the Company had a total of 30,405,600 0.039 The Company had accrued dividends on the Series E Preferred stock of approximately $ 5.3 5.0 At March 31, 2022 and December 31, 2021, there were 3,326 Series F Convertible Preferred Shares and Warrants The Series F Preferred Stock has a stated value of $ 5,000 8 0.50 February 10, 2020 On October 30, 2019, the Company repurchased 20 150,000 100,000 100,000 On March 19, 2021, the exercise price of the Series F warrants was adjusted from $ 0.50 0.05 25,900 518,000 31,000 0.16 262.27 .46 .53 On October 15, 2021, the Company issued 37,043 3 3,521 As of November 9, 2021, the three-year anniversary of the closing of the Series F Preferred stock offering, all outstanding Series F Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders. As of December 31, 2021, the Company has not provided notice of conversion to the holders of the Series F Preferred stock. As of December 31, 2021, the Company had a total of 3,088,500 The Company had accrued dividends on the Series F Preferred stock of approximately $ 523,000 and $ 448,000 , as of March 31, 2022, and December 31, 2021, respectively. At March 31, 2022 and December 31, 2021, there were 358 Series G Convertible Preferred Shares The Series G Preferred Stock has a stated value of $ 5,000 8 0.50 As of March 31, 2022, no Common Stock On June 8, 2021, an investor converted 8 10,000 101,010 On June 8, 2021, the Company issued 53,571 75,000 On July 30, 2021, and investor converted 50 250,000 500,000 On August 11, 2021, the Company issued 100,000 56,464 On August 18, 2021, the Company issued 100,000 62,220 On September 22, 2021, the Company issued 300,148 39,290 On October 4, 2021, the Company issued 255,540 20 27,770 On October 4, 2021, the Company issued 59,523 10,859 On October 5, 2021, the Company issued 385,414 30 42,707 On October 8, 2021, the Company issued 51,414 4 5,707 On October 8, 2021, the Company issued 59,523 12,233 On October 15, 2021, the Company issued 37,043 3 3,521 On November 4, 2021, the Company issued 153,227 250,000 On December 6, 2021, the Company issued 96,091 18,745 During the twelve-month period ending December 31, 2021, the company issued 3,366,012 98,141 70,160 554,000 386,000 On January 27, 2022, the Company issued 254,401 shares of common stock upon the conversion of $ 9,500 principal and $ 422 of interest on the June 2021 convertible note that were valued at fair value based on the quoted trading prices on the conversion dates aggregating approximately $ 28,000 18,000 23,000 23,000 5,000 On March 15, 2022, the Company issued 50,000 shares of common stock to a convertible note investor as a commitment fee which was valued at its relative fair value of $ 3,596 . On March 15, 2022, the Company issued 200,00 0 shares of common stock to an investment banker for commissions due under a banking agreement for issuance of a convertible note. The shares were recorded at their fair value of approximately $ 14,384 . Warrants As of March 31, 2022, there were 79,316,071 common stock warrants outstanding, with a weighted average exercise price of $ 0.05 per share, with annual expirations as follows: Schedule of Stockholders’ Equity Note, Warrants or Rights Warrant Expiry Summary: Shares 2023 2024 2025 2026 Issued with Series E Preferred Stock 30,405,600 30,405,600 — — — Issued with Series F Preferred Stock 3,088,500 3,088,500 — — — Issued with Convertible Notes (CVN) 45,473,238 — 2,901,098 25,660,167 6,911,974 Other 348,733 10,080 335,452 3,201 — Total Warrants 79,316,071 33,504,180 3,236,550 35,663,368 6,911.974 Schedule of Warrants Warrant Rollforward Shares Warrants as of December 31, 2021 74,625,139 Issued as a result of price adjustments on CVN 2,665,663 Variable quantity of warrants related to February 2020 note 2,025,259 Warrants as of March 31, 2022 79,316,071 Warrants outstanding as of March 31, 2022, included 78,014,958 price adjustable warrants. The intrinsic value of 79,316,071 2.7 As discussed in Note 2 above, the Company has issued convertible notes and warrants with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock and various default provisions related to the payment of the notes in Company stock. The number of shares of common stock to be issued under the convertible notes and warrants is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is therefore, indeterminate. Due to the fact that the number of shares of common stock issuable exceed the Company’s authorized share limit as of March 31, 2022, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative as of that date. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the warrants were recorded as derivative liabilities. On March 31, 2022, the Company evaluated all outstanding warrants to determine whether these instruments are tainted and, due to reasons discussed above, all warrants outstanding were considered tainted and were therefore, accounted for as derivative liabilities. Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain warrants to reduce the conversion price to $ 0.039

Stock Incentive Plans

Stock Incentive Plans	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock Incentive Plans	NOTE 8 - Stock Incentive Plans Stock Options The following table summarizes stock option activity for the three-month period ended March 31, 2022: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2021 384,050 $ 0.97 Options expired / forfeited (4,050 ) 1.70 Outstanding, March 31, 2022 380,000 0.98 Exercisable, March 31, 2022 380,000 $ 0.98 No stock options were granted during the three-month period ended March 31, 2022. The following table summarizes additional information on the Company’s stock options outstanding at March 31, 2022: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.98 380,000 1.09 $ 0.98 380,000 $ 0.98 Totals 380,000 1.09 $ 0.98 380,000 $ 0.98 As of March 31, 2022, the Company had no unrecognized compensation expense related to unvested stock options. Total expense related to stock options was zero 8,000 As of March 31, 2022, the intrinsic value of options outstanding or exercisable was zero there were no options outstanding with an exercise price less than $ 0.07

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9 - Commitments and Contingencies Litigation Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors. Leases The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs. Share Repurchase Agreement On October 30, 2019, the Company repurchased 20 150,000 100,000 100,000 Licensing Agreement – MLR 1019 On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC (“MP”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use MP’s Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 million upon meeting certain performance milestones, as well as a royalty of 5 % of gross sales. The license terminates upon the last expiration of the patents licensed by the Company, which is presently 2034 subject extensions and renewals of any of such patents. If the Company fails to have its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using MP’s data shall terminate. Additionally, if the Company has completed the necessary steps to effect an Uplisting Event, the Company will have the option to purchase all rights held by MP on the MLR-1019 licensed products in consideration for 10 % of the outstanding shares of the Company’s common stock (immediately post Uplisting Event) and 2.5 % royalty of future gross product sales. As of March 31, 2022, no performance milestones had been met under the agreement. Licensing Agreement – MLR 1023 On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of Melior’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 8 12 Under the original terms of the agreement if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise On October 20, 2021, the Company expanded the exclusive licensing agreement with Melior Pharmaceuticals I, Inc. to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. On November 17, 2021, Melior Pharmaceuticals I, Inc. extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising On February 16, 2022, an addendum to the licensing agreement dated August 4, 2021, was executed by the Company and Melior Pharmaceuticals I, Inc, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022 As of March 31, 2022, no performance milestones had been met under the agreement.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 - Subsequent Events Forbearance Agreement On April 19, 2022, a majority of the noteholders (the “Purchasers”) of the secured non-convertible promissory notes of the Company issued between June 18, 2019, and August 5, 2019 which matured on August 5, 2020 consented to forbear collection efforts until September 30, 2022. Accordingly, the collateral agent for the note holders in consideration of the signed noteholder agreements agreed to forbear all notes outstanding. The agreement to forbear was subject to the closing of a private placement transaction resulting in at least $ 2 Issuance of Notes Payable On May 11, 2022, the Company entered into a Securities Purchase Agreement (the “SPA”) with investors (the “Purchasers”) whereby the Company issued the Purchasers Original Issue Discount Promissory Notes in the aggregate principal amount of $ 2,222,222 222,222 (the “Notes”) for a purchase price of $ 2,000,000 and warrants to purchase 22,222,218 shares of the Company’s common stock (the “Warrants”), pursuant to the terms and conditions of the SPA and secured by a Security Agreement as described below. The Company received total consideration of $ 1,712,000 after debt issuance costs of $ 288,000 . The Notes are convertible and the Warrants are exercisable into shares of common stock at conversion and exercise prices of $ 0.04 per share. The Notes are due on the earliest to occur of (i) the 12 month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a 125% of the outstanding principal, accrued interest and other amounts owing thereon. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12 month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest The Warrants are exercisable for a 66 November 11, 2027 0.04 The Company’s obligations under the Notes are secured by a first priority lien on all of the assets of the Company and its wholly-owned subsidiaries pursuant to a Security Agreement, dated May 11, 2022 (the “Security Agreement”) by and among the Company, its wholly-owned subsidiaries, the Purchasers, and the lead investor as the collateral agent.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results for the year ending December 31, 2022 or for any future period.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive.
Going Concern and Management’s Liquidity Plans	Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2022, the Company had cash and cash equivalents of approximately $ 40,000 25.5 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $ 74,000 216,000 53.5 In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issues arising from the COVID-19 pandemic, the Ukraine war and inflation and the Federal Reserve interest rate increases in response, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of March 31, 2022, the Company had approximately $ 40,000 The Company deposits its cash with major financial institutions and may at times exceed the federally insured limit. At March 31, 2022, the Company’s cash balance did not exceed the federal insurance limit.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of March 31, 2022, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.2 1.63 2.45 244.5 309.03 0.88 no Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at March 31, 2022 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,169 $ 7,169 Total $ - $ - $ 7,169 $ 7,169 A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (In thousands) Warrants Notes Total Three-Months Ended March 31, 2022 (In thousands) Warrants Notes Total Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 Initial valuation of derivative liabilities included in debt discount — 163 163 Initial valuation of derivative liabilities included in derivative expense — 10 8 108 Reclassification of derivative liabilities loss to gain on debt extinguishment — (23 ) (23 ) Change in fair value included in derivative expense (103 ) (673 ) (776 ) Balance at March 31, 2022 $ 5,233 $ 1,936 $ 7,169 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.
Convertible Debt and Warrant Accounting	Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year. The adoption by the Company as of January 1, 2022 did not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2022 2021 March 31, (in thousands except share and per share data) 2022 2021 Numerator Net loss $ (74 ) $ (428 ) Preferred stock dividends (364 ) (882 ) Net Loss allocable to common stockholders $ (438 ) $ (1,310 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 17,179,188 11,187,531 Net loss per share of common stock, basic and diluted Net loss per share, basic and diluted $ (0.03 ) $ (0.12 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Three-Months Ended March 31, 2022 2021 Stock options outstanding 380,000 387,550 Convertible notes 53,901,211 18,785,631 Warrants 79,316,071 62,532,312 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 43,896,887 42,737,413 Series F Preferred Stock 4,627,203 4,374,978 Total 182,238,039 128,934,551 As of March 31, 2022, the Company’s fully diluted common stock equivalents exceeded the 180,000,000
Stock-Based Compensation	Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Fair Value Measurements	Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at March 31, 2022 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,169 $ 7,169 Total $ - $ - $ 7,169 $ 7,169
Schedule of Roll Forward of Level 3 Financial Instruments	A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (In thousands) Warrants Notes Total Three-Months Ended March 31, 2022 (In thousands) Warrants Notes Total Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 Initial valuation of derivative liabilities included in debt discount — 163 163 Initial valuation of derivative liabilities included in derivative expense — 10 8 108 Reclassification of derivative liabilities loss to gain on debt extinguishment — (23 ) (23 ) Change in fair value included in derivative expense (103 ) (673 ) (776 ) Balance at March 31, 2022 $ 5,233 $ 1,936 $ 7,169
Schedule of Earnings Per Share, Basic and Diluted	The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2022 2021 March 31, (in thousands except share and per share data) 2022 2021 Numerator Net loss $ (74 ) $ (428 ) Preferred stock dividends (364 ) (882 ) Net Loss allocable to common stockholders $ (438 ) $ (1,310 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 17,179,188 11,187,531 Net loss per share of common stock, basic and diluted Net loss per share, basic and diluted $ (0.03 ) $ (0.12 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 Three-Months Ended March 31, 2022 2021 Stock options outstanding 380,000 387,550 Convertible notes 53,901,211 18,785,631 Warrants 79,316,071 62,532,312 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 43,896,887 42,737,413 Series F Preferred Stock 4,627,203 4,374,978 Total 182,238,039 128,934,551

Notes Payable and Convertible_2

Notes Payable and Convertible Promissory Notes (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Promissory Notes	The following table summarizes the Company’s outstanding convertible notes as of March 31, 2022, and December 31, 2021: Schedule of Convertible Promissory Notes (in thousands) March 31, 2022 December 31, 2021 Convertible Notes $ 1,756 $ 1,516 Unamortized discounts and fees (605 ) (530 ) Convertible Notes Payable $ 1,151 $ 986
Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode	During the three months period ended March 31, 2022, the fair value of the derivative liabilities was estimated at issuance and at March 31, 2022, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.0 0.88 Volatility 245 309 % Risk-free interest rate 1.28 2.45 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Stockholders’ Equity Note, Warrants or Rights	Schedule of Stockholders’ Equity Note, Warrants or Rights Warrant Expiry Summary: Shares 2023 2024 2025 2026 Issued with Series E Preferred Stock 30,405,600 30,405,600 — — — Issued with Series F Preferred Stock 3,088,500 3,088,500 — — — Issued with Convertible Notes (CVN) 45,473,238 — 2,901,098 25,660,167 6,911,974 Other 348,733 10,080 335,452 3,201 — Total Warrants 79,316,071 33,504,180 3,236,550 35,663,368 6,911.974
Schedule of Warrants	Schedule of Warrants Warrant Rollforward Shares Warrants as of December 31, 2021 74,625,139 Issued as a result of price adjustments on CVN 2,665,663 Variable quantity of warrants related to February 2020 note 2,025,259 Warrants as of March 31, 2022 79,316,071

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Share Based Payments Arrangement, Option Activity	The following table summarizes stock option activity for the three-month period ended March 31, 2022: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2021 384,050 $ 0.97 Options expired / forfeited (4,050 ) 1.70 Outstanding, March 31, 2022 380,000 0.98 Exercisable, March 31, 2022 380,000 $ 0.98
Schedule of Share Based Payment Arrangement, Option, Exercise Price Range	The following table summarizes additional information on the Company’s stock options outstanding at March 31, 2022: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.98 380,000 1.09 $ 0.98 380,000 $ 0.98 Totals 380,000 1.09 $ 0.98 380,000 $ 0.98

Schedule of Fair Value Measurem

Schedule of Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	$ 7,169	$ 7,697
Total	7,169
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	7,169
Total	$ 7,169

Schedule of Roll Forward of Lev

Schedule of Roll Forward of Level 3 Financial Instruments (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Short-Term Debt [Line Items]
Balance at December 31, 2021	$ 7,697
Initial valuation of derivative liabilities included in debt discount	163
Initial valuation of derivative liabilities included in derivative expense	108
Reclassification of derivative liabilities loss to gain on debt extinguishment	(23)
Change in fair value included in derivative expense	(776)
Balance at March 31, 2022	7,169
Warrants [Member]
Short-Term Debt [Line Items]
Balance at December 31, 2021	5,336
Initial valuation of derivative liabilities included in debt discount
Initial valuation of derivative liabilities included in derivative expense
Reclassification of derivative liabilities loss to gain on debt extinguishment
Change in fair value included in derivative expense	(103)
Balance at March 31, 2022	5,233
Convertible Notes [Member]
Short-Term Debt [Line Items]
Balance at December 31, 2021	2,361
Initial valuation of derivative liabilities included in debt discount	163
Initial valuation of derivative liabilities included in derivative expense	10
Reclassification of derivative liabilities loss to gain on debt extinguishment	(23)
Change in fair value included in derivative expense	(673)
Balance at March 31, 2022	$ 1,936

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounting Policies [Abstract]
Net loss	$ (74)	$ (428)
Preferred stock dividends	(364)	(882)
Net Loss allocable to common stockholders	$ (438)	$ (1,310)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted	17,179,188	11,187,531
Net loss per share, basic and diluted	$ (0.03)	$ (0.12)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	182,238,039	128,934,551
Stock Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	380,000	387,550
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	53,901,211	18,785,631
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	79,316,071	62,532,312
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	66,667	66,667
Series D Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	50,000	50,000
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	43,896,887	42,737,413
Series F Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,627,203	4,374,978

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cash and cash equivalents	$ 40,000
Working capital	25,500,000
Net loss	74,000	$ 428,000
Net cash used in operating activities	216,000	$ 46,000
Accumulated deficit	53,455,000		$ 53,017,000
Cash equivalents	40,000		$ 76,000
Fair value, net asset liability	$ 0
Common stock, shares authorized	180,000,000		180,000,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Fair value assumptions, risk free interest rate	1.63%
Fair value assumptions, volatility rate	244.50%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Fair value assumptions, risk free interest rate	2.45%
Fair value assumptions, volatility rate	309.03%
Fair value assumptions, expected term	10 months 17 days
Fair Value, Inputs, Level 3 [Member]
Property, Plant and Equipment [Line Items]
Long-term debt, fair value	$ 7,200,000

Prepaid Expenses (Details Narra

Prepaid Expenses (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expenses
Prepaid Expense	$ 130,000	$ 120,000

Schedule of Convertible Promiss

Schedule of Convertible Promissory Notes (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible Notes	$ 1,756	$ 1,516
Unamortized discounts and fees	(605)	(530)
Convertible Notes Payable	$ 1,151	$ 986

Schedule of Fair Value of Deriv

Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details)	Mar. 31, 2022
Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Risk-free interest rate	0
Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Term (in years)	0 years
Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Term (in years)	10 months 17 days
Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	245
Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	309
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	1.28
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	2.45

Notes Payable and Convertible_3

Notes Payable and Convertible Promissory Notes (Details Narrative)	Mar. 15, 2022USD ($)shares	Jan. 27, 2022USD ($)$ / sharesshares	Jan. 05, 2022	Nov. 30, 2021$ / sharesshares	Nov. 29, 2021USD ($)shares	Nov. 15, 2021$ / sharesshares	Nov. 04, 2021shares	Oct. 27, 2021	Oct. 12, 2021	Oct. 07, 2021USD ($)$ / sharesshares	Oct. 04, 2021USD ($)$ / sharesshares	Sep. 13, 2021USD ($)shares	Aug. 17, 2021USD ($)$ / sharesshares	Aug. 16, 2021USD ($)shares	Aug. 11, 2021USD ($)$ / sharesshares	Jul. 30, 2021shares	Jul. 29, 2021USD ($)shares	Jun. 25, 2021USD ($)$ / sharesshares	Jun. 25, 2021USD ($)$ / sharesshares	Apr. 12, 2021USD ($)$ / sharesshares	Mar. 19, 2021USD ($)$ / sharesshares	Jan. 31, 2021USD ($)$ / sharesshares	Oct. 30, 2020USD ($)$ / sharesshares	Jun. 26, 2020USD ($)$ / shares	May 05, 2020$ / shares	Feb. 05, 2020USD ($)	Dec. 28, 2019	Jul. 31, 2021	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)shares	Jan. 31, 2022$ / shares	Jan. 02, 2022	Nov. 09, 2021	Apr. 30, 2021	Aug. 05, 2020	Jun. 15, 2020	Dec. 31, 2019USD ($)	Oct. 30, 2019$ / shares	Aug. 05, 2019USD ($)
Short-Term Debt [Line Items]
Debt instrument, interest rate																													140.00%
Convertible Notes Payable, Current																													$ 1,151,000		$ 986,000
Debt discount to be amortized																													605,000		$ 530,000
Debt discount																													175,000	$ 77,000
Loss on fair value of derivative liabilities																													667,000
Interest Expense, Related Party																													$ 25,000	25,000
Warrants to purchase common stock | shares		716,320																											79,316,071		74,625,139
Warrants exercise price per share | $ / shares																		$ 0.08	$ 0.08										$ 0.05
Debt Conversion, Original Debt, Interest Rate of Debt			16.00%
Payments of Debt Issuance Costs																													$ 20,000	2,000
February 2020 Convertible Note [Member]
Short-Term Debt [Line Items]
Principal amount																													457,359		$ 98,141
Interest expense																															70,160
Debt conversion amount																															$ 554,000
Debt Conversion, Converted Instrument, Shares Issued | shares																															3,366,012
Interest payable																													126,000
Senior Secured Convertible Promissory Note One [Member]
Short-Term Debt [Line Items]
Principal amount																							$ 111,111						$ 111,111
Debt issuance costs																							$ 9,000
Debt instrument, interest rate																							10.00%						125.00%
Interest expense																													$ 5,000	4,700
Accured interest																													24,000
Debt Instrument, Interest Rate, Effective Percentage																																			18.00%
Conversion price | $ / shares																							$ 0.07																$ 0.05
Warrants term																					11 months 1 day
Debt discount to be amortized																							$ 6,000
Debt discount																													$ 1,900	57,000
Shares Issued, Price Per Share | $ / shares																							$ 0.08
Premimum Description																													The 25% premium will be recorded once a demand occurs
Proceeds from issuance of secured debt																							$ 100,000
Convertible, Beneficial Conversion Feature																							45,000
Beneficial Conversion Feature																							$ 69,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger																							70.00%
Warrants to purchase common stock | shares		428,718																			952,379		1,587,301
Warrants exercise price per share | $ / shares																					$ 0.05
Deemed dividend																					$ 57,000
Senior Secured Convertible Promissory Note One [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt and warrant exercise price per share | $ / shares		$ 0.049
Senior Secured Convertible Promissory Note One [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt and warrant exercise price per share | $ / shares		$ 0.039
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Volatility																					0.16
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Volatility																					262.27
Senior Secured Convertible Promissory Note - January 2021 [Member]
Short-Term Debt [Line Items]
Principal amount																						$ 52,778
Debt issuance costs																						2,000
Interest expense																													$ 2,400	1,200
Accured interest																													$ 9,000
Convertible Notes Payable, Current																						$ 47,500
Debt Instrument, Interest Rate, Effective Percentage																						10.00%							125.00%
Conversion price | $ / shares																					$ 0.05	$ 0.07
Warrants term																					11 months 19 days
Debt discount to be amortized																						$ 2,000
Debt discount																														18,000
Debt issuance costs																														300
Premimum Description																													The 25% premium will be recorded once a demand occurs
Warrants exercise price per share | $ / shares																						$ 0.08
Deemed dividend																					$ 27,000
Debt Instrument, Convertible, Conversion Ratio																						0.70
Warrants issued | shares																					452,372	753,968
Debt default interest rate																												18.00%
Fair value method																						$ 1,000
Debt instrument, unamortized discount, current																						35,000
Additional warrants issued | shares		340,250
Notes payable																													$ 52,778
Senior Secured Convertible Promissory Note - January 2021 [Member] | Investor and lender [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized																						5,278
Senior Secured Convertible Promissory Note - January 2021 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt and warrant exercise price per share | $ / shares		$ 0.049
Senior Secured Convertible Promissory Note - January 2021 [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt and warrant exercise price per share | $ / shares		0.039
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Volatility																					0.16
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Volatility																					262.27
Senior Secured Convertible Promissory Note April 2021 [Member]
Short-Term Debt [Line Items]
Principal amount																				$ 66,667									$ 66,667
Debt instrument, interest rate																				10.00%									125.00%
Interest expense																													$ 3,000
Accured interest																													$ 9,100
Convertible Notes Payable, Current																				$ 60,000
Debt Instrument, Interest Rate, Effective Percentage																				10.00%
Conversion price | $ / shares		$ 0.039		$ 0.05
Debt conversion rate																				70.00%
Warrants term																				1 year
Debt discount to be amortized																				$ 34,000
Debt discount																				3,000
Premimum Description																													The 25% premium will be recorded once a demand occurs
Warrants to purchase common stock | shares		322,949		131,667
Warrants exercise price per share | $ / shares				$ 0.05
Debt default interest rate									18.00%
Debt instrument, unamortized discount, current																				$ 6,667
Senior Secured Convertible Promissory Note April 2021 [Member] | Investor [Member]
Short-Term Debt [Line Items]
Warrants term																				5 years
Warrants to purchase common stock | shares																				800,000
Warrants exercise price per share | $ / shares																				$ 0.095
Senior Secured Convertible Promissory Note April 2021 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Conversion price | $ / shares		$ 0.0525
Senior Secured Convertible Promissory Note April 2021 [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Conversion price | $ / shares		$ 0.039
Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Volatility																				0.89
Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Volatility																				240.64
April 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Shares issued for warrants exercise | shares							153,227
Cashless exercise of warrants | shares							250,000
Senior Secured Convertible Promissory Note - June 2021 [Member]
Short-Term Debt [Line Items]
Principal amount																		$ 66,500	$ 66,500										$ 57,000
Debt instrument, interest rate																		10.00%	10.00%
Debt maturity date																		Jun. 25, 2022
Interest expense		$ 421
Accured interest																													8,800
Debt Instrument, Interest Rate, Effective Percentage																		5.00%	5.00%
Conversion price | $ / shares		$ 0.039																$ 0.075	$ 0.075
Debt conversion rate																		65.00%
Warrants term																		3 years	3 years
Debt discount to be amortized																		$ 5,040	$ 5,040										28,900
Debt discount																		15,784
Debt issuance costs																			$ 9,300
Debt conversion amount		$ 9,500
Debt Conversion, Converted Instrument, Shares Issued | shares		254,401
Loss on extinguishment of debt		$ 18,000
Gain on extinguishment of debt																		23,000
Net loss on extinguishment of debt		5,000
Proceeds from issuance of secured debt																		$ 63,000
Warrants to purchase common stock | shares																		800,000	800,000
Warrants exercise price per share | $ / shares																		$ 0.095	$ 0.095
Debt instrument, unamortized discount, current																		$ 3,500	$ 3,500
Warrants and Rights Outstanding																		$ 76,000	76,000
Number of shares issued | shares																		47,547
Derivative liabilities																		$ 102,823	102,823
Derivative expense																		87,039
Debt discount																		66,500	66,500
Discount related to issuance costs																		$ 9,300	$ 9,300
Debt Securities, Trading		28,000
Derivative, Fair Value, Net		$ 23,000
Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-Term Debt [Line Items]
Principal amount															$ 220,500														220,500
Debt issuance costs															$ 30,000
Debt instrument, interest rate															10.00%																			24.00%
Interest expense																													12,400
Accured interest																													28,200
Conversion price | $ / shares		$ 0.039		0.05											$ 0.075
Debt conversion rate		65.00%													65.00%
Debt discount to be amortized															$ 220,500														79,700
Debt discount															$ 106,505														54,400
Warrants to purchase common stock | shares													800,000		800,000
Warrants exercise price per share | $ / shares		$ 0.039		$ 0.05
Debt instrument, unamortized discount, current															$ 10,500
Additional warrants issued | shares				720,000
Warrants and Rights Outstanding															$ 210,000
Number of shares issued | shares															140,000
Derivative liabilities															$ 340,893
Derivative expense															$ 234,388
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares		428,718
Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-Term Debt [Line Items]
Principal amount													$ 220,500																220,500
Debt issuance costs													$ 30,000
Debt instrument, interest rate													10.00%
Debt maturity date								Feb. 17, 2023
Interest expense																													12,400
Accured interest																													27,800
Conversion price | $ / shares		$ 0.039											$ 0.075
Debt conversion rate		65.00%											65.00%
Debt discount to be amortized																													123,200
Debt discount													$ 100,571																34,700
Warrants exercise price per share | $ / shares		$ 0.039
Debt and warrant exercise price per share | $ / shares		$ 0.039
Debt instrument, unamortized discount, current													10,500
Warrants and Rights Outstanding													210,000
Derivative liabilities													398,404
Derivative expense													$ 297,833
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares		428,718
Debt term													1 year
Secured Convertible Promissory Note - August 17, 2021 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Conversion price | $ / shares													$ 0.08
Convertible Promissory Note - October 4, 2021 [Member]
Short-Term Debt [Line Items]
Principal amount											$ 131,250																		131,250
Debt issuance costs											$ 15,000
Debt instrument, interest rate											10.00%																						16.00%
Interest expense																													5,000
Accured interest																													8,200
Conversion price | $ / shares		$ 0.039									$ 0.075
Debt discount to be amortized											$ 131,250																		66,900
Debt discount											$ 77,891																		32,400
Debt Conversion, Converted Instrument, Shares Issued | shares											43,459
Warrants to purchase common stock | shares											476,190
Debt instrument, unamortized discount, current											$ 6,250
Warrants and Rights Outstanding											110,000
Derivative liabilities											564,943
Derivative expense											487,052
Discount related to issuance costs											32,109
Aggregate exercise price											45,238
[custom:DebtInstrumentUnamortizedDiscountForIssuanceCosts-0]											$ 15,000
Convertible Promissory Note October 7, 2021 [Member]
Short-Term Debt [Line Items]
Principal amount										$ 131,250																			131,250
Debt issuance costs										$ 15,000
Debt instrument, interest rate										10.00%
Interest expense																													5,000
Accured interest																													8,100
Conversion price | $ / shares		0.039								$ 0.075
Debt discount to be amortized																													68,000
Debt discount										$ 76,517			$ 131,250																32,400
Warrants to purchase common stock | shares										476,190
Debt instrument, unamortized discount, current													6,250
Warrants and Rights Outstanding										$ 110,000
Derivative liabilities										564,184
Derivative expense										487,667
[custom:DebtInstrumentUnamortizedDiscountForIssuanceCosts-0]													$ 15,000
Aggreggate exercise price										$ 45,238
Convertible Promissory Note - March 15, 2022 [Member]
Short-Term Debt [Line Items]
Principal amount	$ 250,000																												250,000
Debt instrument, interest rate	10.00%
Interest expense																													25,000
Accured interest																													25,000
Debt discount to be amortized																													238,400
Debt discount	$ 250,000																												11,600
Debt periodic payment	39,285.71
Proceeds from issuance of secured debt	200,000
Debt instrument, unamortized discount, current	$ 50,000
Number of shares issued | shares	200,000
[custom:DebtInstrumentUnamortizedDiscountForIssuanceCosts-0]	$ 34,384
Proceeds from Convertible Debt	180,000
Payments of Debt Issuance Costs	20,000
Guaranteed interest contracts	$ 250
Convertible Promissory Note - March 15, 2022 [Member] | Investor [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares	50,000
Warrant [Member] | Senior Secured Convertible Promissory Note One [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized																							$ 66,000
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member]
Short-Term Debt [Line Items]
Debt issuance costs																						1,000
Debt discount to be amortized																						32,000
Debt discount																						$ 3,000
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Volatility																						0.45
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Volatility																						240.83
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member]
Short-Term Debt [Line Items]
Conversion price | $ / shares																		$ 0.075	$ 0.075
Warrants term																				11 months 15 days
Debt discount																				$ 3,700
Deemed dividend																		$ 11,000	$ 11,000
Warrants issued | shares																		213,333
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Volatility																		0.92	0.92
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Volatility																		247.52	247.52
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member]
Short-Term Debt [Line Items]
Interest expense																													3,500
Conversion price | $ / shares				$ 0.05
Warrants term															6 months 25 days			7 months 6 days	7 months 6 days
Debt discount to be amortized																		$ 37,916	$ 37,916
Debt discount																		$ 15,784											9,800
Warrants exercise price per share | $ / shares				$ 0.05											$ 0.075
Deemed dividend															$ 25,000
Warrants issued | shares															213,333
Additional warrants issued | shares				506,667
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Volatility															0.81			0.48	0.48
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Volatility															209			302.11	302.11
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-Term Debt [Line Items]
Warrants term															1 year
Debt discount to be amortized															$ 56,454
Warrants exercise price per share | $ / shares															$ 0.095
Discount related to issuance costs															$ 30,000
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Volatility															0.81
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Volatility															253
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-Term Debt [Line Items]
Warrants term															1 year
Debt discount to be amortized															$ 62,220
Debt issuance costs															$ 30,000
Warrants exercise price per share | $ / shares													$ 0.095
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Volatility															0.77
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Debt conversion rate						24.00%
Volatility															254
Warrant [Member] | Convertible Promissory Note - October 4, 2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares											$ 0.095
Warrant [Member] | Convertible Promissory Note October 7, 2021 [Member]
Short-Term Debt [Line Items]
Warrants exercise price per share | $ / shares										$ 0.095
Warrant [Member] | Secured Convertible Promissory Note Two [Member]
Short-Term Debt [Line Items]
Debt discount																													163,000
Loss on fair value of derivative liabilities																													776,000
Derivative liabilities																													271,000
Derivative expense																													108,000
Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued | shares																500,000
Common Stock [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized															$ 17,041
Common Stock [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized															17,209
Number of shares issued | shares													112,601
Common Stock [Member] | Convertible Promissory Note - October 4, 2021 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized											$ 77,891
Common Stock [Member] | Convertible Promissory Note October 7, 2021 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized													$ 33,483
Common Stock [Member] | Convertible Promissory Note - March 15, 2022 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized	$ 3,596
Ten Convertible Notes [Member]
Short-Term Debt [Line Items]
Principal amount																													1,500,000
Convertible Debt [Member]
Short-Term Debt [Line Items]
Conversion price | $ / shares																																$ 0.039
Debt conversion amount																															$ 554,000
Debt Conversion, Converted Instrument, Shares Issued | shares																															3,366,012
Debt periodic payment																															$ 168,300
Loss on extinguishment of debt																															386,000
Loss on fair value of derivative liabilities																															245,000
Gain on extinguishment of debt																															245,000
Net loss on extinguishment of debt																															$ 141,000
Convertible Debt [Member] | Senior Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate																																				18.00%
Conversion price | $ / shares		$ 0.039																														$ 0.039
Debt conversion rate		65.00%
Convertible Debt [Member] | Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount																													$ 58,055
Debt instrument, interest rate																													140.00%
Premimum Description																													The 40% premium will be recorded once a demand occurs
Accrued interest																													$ 18,000
Convertible Debt [Member] | Senior Secured Convertible Promissory Note One [Member]
Short-Term Debt [Line Items]
Debt issuance costs																							4,000
Debt discount																							$ 5,000
Convertible Debt [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized															106,505
Convertible Debt [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-Term Debt [Line Items]
Conversion price | $ / shares						$ 0.05
Debt discount to be amortized															$ 100,571
Warrants to purchase common stock | shares						720,000
Warrants exercise price per share | $ / shares						$ 0.05
Convertible Debt [Member] | Convertible Promissory Note October 7, 2021 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized													$ 76,517
Convertible Debt [Member] | Convertible Promissory Note - March 15, 2022 [Member]
Short-Term Debt [Line Items]
Debt discount to be amortized	$ 162,020
Convertible Note [Member] | Senior Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount																								$ 58,055
Debt issuance costs																								$ 14,000
Debt instrument, interest rate																								10.00%
Debt maturity date																								Dec. 26, 2020
Debt Instrument, Interest Rate, Effective Percentage																								10.00%
Conversion price | $ / shares																								$ 0.02
Debt conversion rate																								65.00%
Debt discount to be amortized																								$ 5,555
Proceeds from issuance of secured debt																								52,500
Convertible, Beneficial Conversion Feature																								50,000
Beneficial Conversion Feature																								$ 203,000
Term Loan Subscription Agreements [Member]
Short-Term Debt [Line Items]
Principal amount																																								$ 5,700,000
Interest expense																													2,600	2,600
Registration Rights Agreement [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-Term Debt [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares															100,000
Registration Rights Agreement [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-Term Debt [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares													100,000
Registration Rights Agreement [Member] | Convertible Promissory Note - October 4, 2021 [Member]
Short-Term Debt [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares											59,523
Registration Rights Agreement [Member] | Convertible Promissory Note October 7, 2021 [Member]
Short-Term Debt [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares										59,523
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares										52,632
Accredited Investors [Member] | Term Loan Subscription Agreements [Member]
Short-Term Debt [Line Items]
Principal amount																																						$ 5,700,000
Debt issuance costs																																						$ 707,000
Debt instrument, interest rate																																						12.00%
Debt instrument, interest during period																											15.00%
Debt maturity date																															Jun. 28, 2020
Interest expense																													210,000	$ 210,000
Accured interest																													2,200,000
Repayments of Debt																													5,700,000
Debt Instrument, Periodic Payment, Interest																													$ 2,200,000
Accredited Investors [Member] | Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Principal amount																										$ 550,500
Debt instrument, interest rate																										10.00%											18.00%
Debt maturity date																										Aug. 5, 2020
Convertible Notes Payable, Current																										$ 499,950
Debt Instrument, Interest Rate, Effective Percentage																										10.00%
Conversion price | $ / shares																									$ 0.50
Weighted average Percentage																									70.00%
Debt conversion rate		60.00%																							60.00%
Stock combinations | $ / shares																									$ 0.05
Debt discount to be amortized																										$ 381,000
Shares Issued, Price Per Share | $ / shares		$ 0.039
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Warrants term																										5 years
Debt discount to be amortized																										$ 322,000
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt discount																										21,000
Debt issuance costs																										38,000
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Debt issuance costs																										53,000
Debt discount																										$ 30,000
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Note [Member]
Short-Term Debt [Line Items]
Debt conversion amount					$ 31,150						$ 26,250	$ 32,500		$ 25,000			$ 27,500				$ 25,900
Debt Conversion, Converted Instrument, Shares Issued | shares					623,012						525,000	650,000		500,000			550,000				518,000
Premimum Description																													The 40% premium will be recorded once a demand occurs

Licensing Agreements (Details N

Licensing Agreements (Details Narrative)	Mar. 16, 2018USD ($)
Accrued Liabilities [Member] | Sub-Licensing Agreement [Member]
Upfront payment agreement for license agreement	$ 200,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due to Related Parties	$ 4,000		$ 4,000
Officers And Directors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due from related parties	$ 72,000	$ 42,000

Schedule of Stockholders_ Equit

Schedule of Stockholders’ Equity Note, Warrants or Rights (Details)	Mar. 31, 2022shares
Class of Stock [Line Items]
Warrant shares	79,316,071
Warrant [Member]
Class of Stock [Line Items]
Warrant shares	79,316,071
Expiring in 2023	33,504,180
Expiring in 2024	3,236,550
Expiring in 2025	35,663,368
Expiring in 2026	6,911.974
Convertible Notes [Member]
Class of Stock [Line Items]
Warrant shares	45,473,238
Expiring in 2023
Expiring in 2024	2,901,098
Expiring in 2025	25,660,167
Expiring in 2026	6,911,974
Other [Member]
Class of Stock [Line Items]
Warrant shares	348,733
Expiring in 2023	10,080
Expiring in 2024	335,452
Expiring in 2025	3,201
Expiring in 2026
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares	30,405,600
Expiring in 2023	30,405,600
Expiring in 2024
Expiring in 2025
Expiring in 2026
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares	3,088,500
Expiring in 2023	3,088,500
Expiring in 2024
Expiring in 2025
Expiring in 2026

Schedule of Warrants (Details)

Schedule of Warrants (Details)	3 Months Ended
	Mar. 31, 2022shares
Equity [Abstract]
Warrants, Beginning Balance	74,625,139
Issued as a result of price adjustments on CVN	2,665,663
Variable quantity of warrants related to February 2020 note	2,025,259
Warrants, Ending Balance	79,316,071

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative)	Mar. 15, 2022USD ($)shares	Jan. 27, 2022USD ($)$ / sharesshares	Jan. 27, 2022USD ($)$ / sharesshares	Dec. 06, 2021USD ($)shares	Nov. 23, 2021USD ($)shares	Nov. 04, 2021shares	Oct. 15, 2021USD ($)shares	Oct. 12, 2021USD ($)shares	Oct. 08, 2021USD ($)shares	Oct. 05, 2021USD ($)shares	Oct. 04, 2021USD ($)shares	Sep. 22, 2021USD ($)shares	Aug. 18, 2021USD ($)shares	Aug. 11, 2021USD ($)shares	Jul. 30, 2021USD ($)shares	Jun. 25, 2021USD ($)$ / shares	Jun. 08, 2021USD ($)shares	Mar. 19, 2021USD ($)$ / sharesshares	Oct. 30, 2019USD ($)shares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)$ / sharesshares	Jan. 31, 2022$ / shares	Dec. 31, 2019shares	Jul. 31, 2018shares	Apr. 30, 2018shares	Aug. 31, 2015shares	Mar. 31, 2014shares
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																				100,000		100,000
Stated value per share | $ / shares																				$ 0.01		$ 0.01
Warrant exercise price shares upon conversion of debt | $ / shares																$ 0.08				$ 0.05
Warrant, shares		716,320	716,320																	79,316,071		74,625,139
Warrants outstanding																				79,316,071
Extinguishment of debt | $																				$ 5,000
Stock Issued During Period, Value, Conversion of Convertible Securities | $																				28,000	26,000
Intrinsic value | $																				2,700,000
Convertible Debt [Member]
Class of Stock [Line Items]
Debt conversion | $																						$ 554,000
Common shares issued																						3,366,012
Loss on extinguishment of debt | $																						$ 386,000
[custom:GainOnExtinguishmentOfDebt] | $																						245,000
Extinguishment of Debt, Gain (Loss), Net of Tax | $																						141,000
Debt Instrument, Convertible, Conversion Price | $ / shares																							$ 0.039
April 2021 Convertible Note [Member]
Class of Stock [Line Items]
Cashless exercise of warrants						250,000
Shares issued for warrants exercise						153,227
February 2020 Convertible Note [Member]
Class of Stock [Line Items]
Debt conversion | $																						$ 554,000
Common shares issued																						3,366,012
Principal amount | $																				457,359		$ 98,141
Accrued interest | $																						70,160
Extinguishment of debt | $																						$ 386,000
Senior Secured Convertible Promissory Note [Member] | Convertible Debt [Member]
Class of Stock [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 0.039	$ 0.039																				$ 0.039
Banking Agreement [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues	200			96,091								300,148
Fair value | $	$ 14,384			$ 18,745								$ 39,290
Convertible Note Investor [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues	50,000	254,401							59,523		59,523		100,000	100,000
Fair value | $	$ 3,596								$ 12,233		$ 10,859		$ 62,220	$ 56,464
Accrued interest | $		$ 422
Stock Issued During Period, Value, Conversion of Convertible Securities | $		9,500
Debt Securities, Trading | $		28,000	$ 28,000
Loss on extinguishment of debt | $			18,000
Derivative, Fair Value, Net | $		$ 23,000	23,000
[custom:GainOnExtinguishmentOfDebt] | $																$ 23,000
Extinguishment of Debt, Gain (Loss), Net of Tax | $			$ 5,000
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Warrants outstanding																						3,088,500
Series E Warrants [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares		$ 0.039	$ 0.039
Debt conversion | $																		$ 25,900
Common shares issued																		518,000
Series E Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares																		$ 0.50
Series E Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares																		$ 0.05
Series E Preferred [Member]
Class of Stock [Line Items]
Conversion of shares					15			5	4	30	20				50		8
Accrued dividends | $																	$ 10,000
Number of shares in accrued dividends																	101,010
Stock issued during period, shares, new issues					193,299			64,312	51,414	385,414	255,540				500,000		53,571
Cashless exercise of warrants																	75,000
Conversion of stock, amount converted | $															$ 250,000
Fair value | $					$ 21,649			$ 7,156	$ 5,707	$ 42,707	$ 27,770
Common Stock [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues															500,000
Stock Issued During Period, Value, Conversion of Convertible Securities | $																				$ 2,000	$ 3,000
Series F Warrants [Member]
Class of Stock [Line Items]
Debt conversion | $																		$ 25,900
Common shares issued																		518,000
Series F Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares																		$ 0.50
Series F Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares																		$ 0.05
Series F Preferred [Member]
Class of Stock [Line Items]
Conversion of shares							3
Stock issued during period, shares, new issues							37,043
Fair value | $							$ 3,521
Warrant [Member]
Class of Stock [Line Items]
Warrants outstanding																				79,316,071
Adjustable warrants, shares																				78,014,958
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock designated, shares																				1,000
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock designated, shares																				90,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																				1,200		1,200
Preferred stock designated, shares																												1,200
Preferred stock, shares outstanding																				100		100
Stated value per share | $ / shares																				$ 0.01		$ 0.01
Preferred stock shares issued																				100		100
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																				220		220
Preferred stock designated, shares																											220
Preferred stock, shares outstanding																				40		40
Stated value per share | $ / shares																				$ 0.01		$ 0.01
Preferred stock shares issued																				40		40
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																				3,500		3,500
Preferred stock designated, shares																										3,500
Preferred stock, shares outstanding																				3,326		3,326
Stated value per share | $ / shares																				$ 0.01		$ 0.01
Preferred stock shares issued																				3,326		3,326
Series F Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																				2,200		2,200
Preferred stock designated, shares																									2,200
Preferred stock, shares outstanding																				358		358
Stated value per share | $ / shares																				$ 0.01		$ 0.01
Accrued dividends | $																				$ 523,000		$ 448,000
Warrant, shares																			150,000
Shares repurchased																			20
Shares repurchase | $																			$ 100,000
Warrants held | $																			$ 100,000
Preferred stock shares issued																				358		358
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																				6,000		6,000
Preferred stock designated, shares																								6,000
Preferred stock, shares outstanding																				0		0
Stated value per share | $ / shares																				$ 0.01		$ 0.01
Preferred stock shares issued																				0		0
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding																				100		100
Stated value per share | $ / shares																				$ 5,000
Preferred stock liquidation preference per share | $ / shares																				$ 5,100
Preferred Stock, Voting Rights																				voting rights of 666.67 votes per share
Common stock at a conversion price, per share | $ / shares																				$ 7.50
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding																				40		40
Stated value per share | $ / shares																				$ 5,000
Preferred stock liquidation preference per share | $ / shares																				$ 300
Preferred Stock, Voting Rights																				voting rights of 1,250
Common stock at a conversion price, per share | $ / shares																				$ 4
Preferred stock stated dividend rate																				5.00%
Series E Convertible Preferred Stock and Warrants [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares																				$ 5,000
Common stock at a conversion price, per share | $ / shares																				$ 0.50
Preferred stock stated dividend rate																				8.00%
Antidilution price protection																				Feb. 10, 2020
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding																				3,326		3,326
Warrant exercise price shares upon conversion of debt | $ / shares																				$ 0.039
Deemed dividend | $																		$ 390,000
Accrued dividends | $																				$ 5,300,000		$ 5,000,000
Warrant, shares																				30,405,600
Warrants outstanding																				30,405,600
Series E Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs																		0.16
Series E Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs																		262.27
Series E Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant term																		5 months 4 days
Series E Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant term																		4 months 28 days
Series F Convertible Preferred Stock and Warrants [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares																				$ 5,000
Common stock at a conversion price, per share | $ / shares																				$ 0.50
Preferred stock stated dividend rate																				8.00%
Antidilution price protection																				Feb. 10, 2020
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding																				358		358
Deemed dividend | $																		$ 31,000
Warrants outstanding																				3,088,500
Series F Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs																		0.16
Series F Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs																		262.27
Series F Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant term																		6 months 10 days
Series F Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant term																		5 months 15 days
Series G Convertible Preferred Shares [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares																				$ 5,000
Common stock at a conversion price, per share | $ / shares																				$ 0.50
Preferred stock stated dividend rate																				8.00%
Series G Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares issued																				0

Schedule of Share Based Payment

Schedule of Share Based Payments Arrangement, Option Activity (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-Based Payment Arrangement [Abstract]
Options Outstanding Beginning | shares	384,050
Options outstanding, weighted average exercise price, beginning | $ / shares	$ 0.97
Options expired / forfeited | shares	(4,050)
Options expired/forfeited, weighted average exercise price | $ / shares	$ 1.70
Options Outstanding Ending | shares	380,000
Options outstanding, weighted average exercise price, ending | $ / shares	$ 0.98
Options Exercisable | shares	380,000
Exercisable, weighted average exercise price | $ / shares	$ 0.98

Schedule of Share Based Payme_2

Schedule of Share Based Payment Arrangement, Option, Exercise Price Range (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding | shares	380,000
Weighted- Average Remaining Contractual Life (Years)	1 year 1 month 2 days
Weighted average exercise price	$ 0.98
Number exercisable | shares	380,000
Weighted average exercise price	$ 0.98
Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices	$ 0.98
Number outstanding | shares	380,000
Weighted- Average Remaining Contractual Life (Years)	1 year 1 month 2 days
Weighted average exercise price	$ 0.98
Number exercisable | shares	380,000
Weighted average exercise price	$ 0.98

Stock Incentive Plans (Details

Stock Incentive Plans (Details Narrative) - Share-Based Payment Arrangement, Option [Member] - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 0	$ 8,000
Share based compensation options outstanding exercisable	$ 0.07

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Aug. 24, 2021	Jul. 28, 2021	Oct. 30, 2019	Feb. 16, 2022	Nov. 17, 2021	Mar. 31, 2022	Jan. 27, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Warrants to purchase shares of common stock						79,316,071	716,320	74,625,139
Licensing Agreement MLR1019 [Member]
Loss Contingencies [Line Items]
Debt Instrument, Periodic Payment		$ 21,800,000
Gross sales percentage		5.00%
Option purchase percentage		10.00%
Royalty gross sales percentage		2.50%
Licensing Agreement MLR1019 [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Gross sales percentage	8.00%
Licensing Agreement MLR1019 [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Gross sales percentage	1200.00%
Licensing Agreement MLR1023 [Member]
Loss Contingencies [Line Items]
Debt Instrument, Periodic Payment	$ 21,800,000
License agreement commitments description	if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise			the Company and Melior Pharmaceuticals I, Inc, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022	the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising
Series F Convertible Preferred Stock [Member]
Loss Contingencies [Line Items]
Number of shares repurchased			20
Warrants to purchase shares of common stock			150,000
Stock repurchase			$ 100,000
Value of warrants held			$ 100,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 11, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Subsequent Event [Line Items]
Debt original issue discount		$ 605,000		$ 530,000
Class of Warrant or Right, Outstanding		79,316,071
Payments of Debt Issuance Costs		$ 20,000	$ 2,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Gross proceeds private placement	$ 2,000,000
Payments of Debt Issuance Costs	$ 288,000
Warrant, Exercise Price, Increase	$ 0.04
Notes annual financial payments	(i) the 12 month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a 125% of the outstanding principal, accrued interest and other amounts owing thereon. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12 month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest
Warrants term	66 months
Warrants maturity date	Nov. 11, 2027
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Proceeds from Convertible Debt	$ 1,712,000
Subsequent Event [Member] | Convertible Redeemable Note [Member] | Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	2,222,222
Debt original issue discount	222,222
Proceeds from Convertible Debt	$ 2,000,000
Class of Warrant or Right, Outstanding	22,222,218